Sai Parenterals to Acquire Majority Stake in Bion Therapeutics’ Prescription Business
Sai Parenterals Ltd · Press Release · 17 Nov 2026, 3:41 pm
Sai Parenterals to Acquire Majority Stake in Bion Therapeutics’ Prescription Business Sai Parenterals Limited, via its wholly owned subsidiary SP Analytics, entered a definitive agreement on 16th Nov'26 to acquire a majority stake in Bion Therapeutics India in an all-cash deal expected to close by late Nov'26. The acquisition adds 16 established branded formulations, ~250 field staff, ~20,000 doctor reach, and over 17,000 retail touchpoints across 12 states. Funded through internal accruals, debt, and IPO proceeds, the deal enables in-house manufacturing at TGA/WHO-GMP accredited facilities, expanding domestic commercial scale and margins.
Original exchange filing (PDF)
More announcements from Sai Parenterals Ltd
- Outcome of Board Meeting held on Monday, 16th November, 2026 · 17 Nov 2026
- call conducted on Monday the 2nd day of November, 2026. · 07 Nov 2026
- Audio recording of earning call held on 2nd November, 2026 over call. · 03 Nov 2026
- Investor Presentation for the quarter and half year ended 30th September, 2026 · 02 Nov 2026
- Investor press release on standalone and consolidated unaudited financial results for the quarter ended 30th September, 2026. · 01 Nov 2026
- Statement of variation and deviation for the period ended 30th September, 2026 · 01 Nov 2026
- Financial Results · 01 Nov 2026
- Sai Parenterals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 01 Nov 2026
